This prespecified updated survival and exploratory subgroup efficacy analysis of the phase 3 DESTINY-Breast04 trial shows that trastuzumab deruxtecan treatment in patients with HER2-low metastatic breast cancer leads to continuous survival benefit irrespective of estrogen receptor or hormone receptor status.

Individuals at risk for rheumatoid arthritis exhibit inflammation and immune dysregulation before and during transition to active disease.

Destabilized variants of MS2 and PP7 coat proteins enable improved live-cell imaging of tagged RNAs in mammalian cells by decreasing background signal caused by unbound coat protein–fluorescent protein fusions.

Seasonal changes in time policy, such as switching between Standard Time (SDT) and Daylight Saving Time (DST), have been adopted by many countries,...

Cancer-associated fibroblasts represent a functionally diverse and heterogeneous entity within the solid tumor microenvironment. Mitochondrial transfer from cancer cells to fibroblasts is now shown to...

In a small trial of patients with severe systemic lupus erythematosus and nephritis, treatment with allogeneic T cells with a CD19 chimeric antigen receptor inserted into the T cell receptor locus and...

Epstein–Barr virus infection generates a neuroinvasive B cell subset, which recruits activated T cells to the central nervous system, promoting multiple sclerosis.

Lithium has an essential role in the brain and is deficient early in Alzheimer’s disease, which can be recapitulated in mice and treated with a novel lithium salt that restores the physiological level.

The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of genetically m...

Recently, Kondo et al. engineered the coexpression of a T cell receptor (TCR) and a chimeric antigen receptor (CAR) and developed an antagonism-enforced braking system where TCR signals both enhance a...

Application of microtubule-targeting agents (MTAs) for triple-negative breast cancer (TNBC) is hampered by their limited efficacy and strong systemic …

Key Points. In NHPs, a single CD137-ADC dose post-HCT eliminates PD-1+ effector T-cells, enabling reconstitution of non-pathogenic T-cell subsets.The CD137